Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 563 entries
View as:

Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Phase: N/A Priority: Normal
NCT ID: NCT00755261 Org: User:
Start: 09/30/08 End: 11/30/10 Due: 11/30/11

Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00245011 Org: User:
Start: 10/31/04 End: 03/31/09 Due: 03/31/10

Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05950139 Org: User:
Start: 05/13/24 End: 07/31/29 Due: 07/31/30

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Phase: N/A Priority: Normal
NCT ID: NCT02845323 Org: User:
Start: 05/16/17 End: 12/31/25 Due: 12/31/26

Penclomedine in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00002915 Org: User:
Start: 12/31/96 End: - Due: -

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Phase: N/A Priority: Normal
NCT ID: NCT01700673 Org: User:
Start: 06/30/13 End: 06/30/20 Due: 06/30/21

Prospective Assessment of Symptoms and Quality of Life in Rectal Cancer Patients Receiving Chemo-Radiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00414232 Org: User:
Start: 11/30/06 End: 10/31/10 Due: 10/31/11

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Phase: N/A Priority: Normal
NCT ID: NCT06245889 Org: User:
Start: 05/01/24 End: 06/30/30 Due: 06/30/31

Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma

Phase: N/A Priority: Normal
NCT ID: NCT03843814 Org: User:
Start: 08/31/14 End: 12/13/17 Due: 12/13/18

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Phase: N/A Priority: Normal
NCT ID: NCT06398457 Org: User:
Start: 09/19/24 End: 03/31/27 Due: 03/31/28

Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02749708 Org: User:
Start: 01/30/17 End: 08/14/18 Due: 08/14/19

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03250273 Org: User:
Start: 11/06/17 End: 11/20/20 Due: 11/20/21

Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib

Phase: N/A Priority: Normal
NCT ID: NCT06610682 Org: User:
Start: 04/07/25 End: 05/15/26 Due: 05/15/27

Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00389610 Org: User:
Start: 09/11/06 End: 12/10/22 Due: 12/10/23

Study of Stereotactic Radiotherapy for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03043794 Org: User:
Start: 08/01/17 End: 10/22/23 Due: 10/22/24

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT03607890 Org: User:
Start: 11/16/18 End: 10/31/25 Due: 10/31/26

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Phase: N/A Priority: Normal
NCT ID: NCT05823571 Org: User:
Start: 07/06/23 End: 03/31/30 Due: 03/31/31

Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00897611 Org: User:
Start: 04/30/05 End: - Due: -

KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05254184 Org: User:
Start: 11/01/22 End: 04/01/27 Due: 04/01/28

Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00003802 Org: User:
Start: 02/28/99 End: 10/31/02 Due: 10/31/03

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00305760 Org: User:
Start: 12/31/05 End: 03/31/09 Due: 03/31/10

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT00361296 Org: User:
Start: 09/30/07 End: 01/31/10 Due: 01/31/11

Exploration of Personalized Biomarkers During Neoadjuvant Radiation Therapy for Spinal and Sacral Chordoma

Phase: N/A Priority: Normal
NCT ID: NCT06463262 Org: User:
Start: 06/14/24 End: 07/31/31 Due: 07/31/32

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT02491411 Org: User:
Start: 09/30/15 End: 03/31/18 Due: 03/31/19

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

Phase: N/A Priority: Normal
NCT ID: NCT02490930 Org: User:
Start: 07/31/15 End: 09/30/17 Due: 09/30/18